Purpose: The aim of this study was to provide insight in the use, intensity and toxicity of therapy with capecitabine and oxaliplatin (CAPOX) and capecitabine monotherapy (CapMono) among elderly stage III colon cancer patients treated in everyday clinical practice.
Methods: Data from the Netherlands Cancer Registry were used. All stage III colon cancer patients aged ≥70 years diagnosed in the southeastern part between 2005 and 2012 and treated with CAPOX or CapMono were included. Differences in completion of all planned cycles, cumulative dosages and toxicity between both regimens were evaluated.
Results: One hundred ninety-three patients received CAPOX and 164 patients received CapMono; 33% (n = 63) of the patients receiving CAPOX completed all planned cycles of both agents, whereas 55% (n = 90) of the patients receiving CapMono completed all planned cycles (P < 0.0001). The median cumulative dosage capecitabine was lower for patients treated with CAPOX (163,744 mg/m(2), interquartile range [IQR] 83,397-202,858 mg/m(2)) than for patients treated with CapMono (189,195 mg/m(2), IQR 111,667-228,125 mg/m(2), P = 0.0003); 54% (n = 105) of the patients treated with CAPOX developed grade III-V toxicity, whereas 38% (n = 63) of the patients treated with CapMono developed grade III-V toxicity (P = 0.0026). After adjustment for patient and tumour characteristics, CapMono was associated with a lower odds of developing grade III-V toxicity than CAPOX (odds ratio 0.54, 95% confidence interval 0.33-0.89). For patients treated with CAPOX, the most common toxicities were gastrointestinal (29%), haematological (14%), neurological (11%) and other toxicity (13%). For patients treated with CapMono, dermatological (17%), gastrointestinal (13%) and other toxicity (11%) were the most common.
Conclusion: CAPOX is associated with significantly more grade III-V toxicities than CapMono, which had a pronounced impact on the cumulative dosage received and completion of all planned cycles. In this light, CapMono seems preferable over CAPOX.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejca.2016.03.074 | DOI Listing |
BMC Plant Biol
January 2025
Institute of Chinese Herbel Medicines, Henan Academy of Agricultural Sciences, Zhengzhou , Henan, 450002, China.
Background: WRKY transcription factors constitute one of the largest families of plant transcriptional regulators, playing pivotal roles in plant responses to biotic and abiotic stresses, as well as in hormonal signaling and secondary metabolism regulation. However, a comprehensive analysis of the WRKY family in Carthamus tinctorius (safflower) is lacking. This study aims to identify and characterize WRKY genes in safflower to enhance understanding of their roles in stress responses and metabolic regulation.
View Article and Find Full Text PDFSci Rep
January 2025
Emergency department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Esophageal squamous cell carcinoma (ESCC) is one of the most common digestive malignancies. Our previous studies revealed necroptosis-related lncRNA ENSG00000253385.1 was an independent prognostic factor for ESCC.
View Article and Find Full Text PDFAdv Skin Wound Care
January 2025
At the University of South Carolina, Columbia, South Carolina, USA, J. Benjamin Jackson III, MD, MBA, is Professor of Orthopaedic Surgery and Director of Orthopaedic Research, Department of Orthopaedics; and Yianni Bakaes, BS, and Ben Jacques, BS, are Medical Students, School of Medicine. Chase Gauthier, MD, is Research Fellow, Prisma Health Department of Orthopedics, Columbia, South Carolina. Also at the University of South Carolina, William L. Mills Jr, MD, and Kenny Nguyen, MD, are Medical Residents, School of Medicine; Tyler Gonzalez, MD, MBA, is Assistant Professor of Orthopaedic Surgery, Department of Orthopaedics; and David L. Cone, MD, is Clinical Associate Professor of Family and Preventative Medicine, School of Medicine. The authors have disclosed no financial relationships related to this article. Submitted September 6, 2023; accepted in revised form January 16, 2024.
Objective: To evaluate the effect of hyperbaric oxygen (HBO) therapy on the outcomes of patients with chronic refractory osteomyelitis (CRO) when combined with modern antibiotics with modern delivery methods and/or surgical treatments.
Methods: The authors conducted a retrospective review on 58 patients with CRO from a single institution who underwent HBO therapy along with standard treatment between January 2009 and December 2019. To investigate associations with binary outcomes of interest, they estimated logistic regression models.
Drug Dev Ind Pharm
January 2025
Guangxi Key Laboratory of Drug Discovery and Optimization, School of Pharmacy, Guilin Medical University, Guilin 541199, Guangxi, China.
Objective: Amid the escalating global cancer incidence, the development of effective and safe anticancer drugs is a critical priority in medical research. Addressing the clinical shortcomings of ruthenium-based anticancer drugs are currently a prominent focus of research.
Significance And Methods: Since the pioneering work with platinum derivatives, significant progress has been made in the fundamental studies of metal complexes for the treatment of a wide range of cancers, and there has been a growing interest in their properties and biomedical applications.
Adv Sci (Weinh)
January 2025
Institution Faculty of Arts and Sciences & Center for Advanced Materials Research, Beijing Normal University, Zhuhai, 519087, China.
The oxygen evolution reaction (OER) involves the recombination of diamagnetic hydroxyl (OH) or water (HO) into the paramagnetic triplet state of oxygen (O). The spin conservation of oxygen intermediates plays a crucial role in OER, however, research on spin dynamics during the catalytic process remains in its early stages. Herein, β-Ni(OH) and Fe-doped β-Ni(OH) (NiFe(OH)) are utilized as model catalysts to understand the mechanism of spin magnetic effects at iron (III) sites during OER.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!